Exelixis and Bristol-Myers Squibb achieved positive Phase II data showing that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The study evaluated the safety, tolerability, and clinical activity of XL184 at daily doses of 175 mg or 125 mg in 46 patients with previously treated GBM, including some patients who had received prior antiangiogenic therapy. The overall rate of confirmed partial response in the patients...